Search

Acute infectious and inflammatory diseases of the upper respiratory tract today belong to the category of the most common pathological conditions. Most often they occur in the form of acute nasopharyngitis, acute rhinosinusitis and acute laryngitis, the clinical of which consists of such symptoms as general weakness, hyperthermia, nasal blockage and nasal discharge, dysosmia, pain and tickling in the throat, cough, dysphonia. The need to select a safe and effective mucoactive therapy justifies the use of the phytopreparation in this pathology, the main active ingredient of which is an extract of ivy leaves. Also in the composition of the drug includes anise oil, peppermint oil, eucalyptus oil and levomenthol. The mechanism of action of is associated with α-hederin contained in ivy leaves. This substance, binding to the beta-adrenoreceptors of the bronchi, causes relaxation of their smooth muscles. In addition, thanks to the saponins contained in the leaves of common ivy, a mucolytic and expectorant effect is achieved. Literature data show that ivy leaf preparations significantly reduce the severity of acute respiratory infections of the upper respiratory tract. Virtually none of the patients had severe side effects. Allergic reactions were recorded in less than 0.5% of cases, with no mention of a severe allergic reaction of the anaphylaxis type. Thus, the drug of plant origin in the form of drops can be successfully used in patients with symptoms of acute respiratory diseases.

Acute respiratory disease (ARD) is a common pathology. Untimely diagnosis and treatment, co-morbidities, old age and children under 1 year of age, pregnancy can increase the severity of the condition and lead to complications and death. According to IDSA recommendations, vaccination is an effective way to prevent complications and fatal influenza cases. Vaccination is primarily for people at risk of serious illness. In cases of suspected influenza, molecular diagnostics is recommended. At the same time, treatment of suspected influenza should be prescribed immediately, without waiting for laboratory confirmation of the diagnosis. Etiotropic treatment aimed at suppressing virus replication should be the first priority in the treatment of acute respiratory viral infections. Bacterial agents may be the primary cause of respiratory diseases or may complicate viral diseases. In the presence of a bacterial pathogen, antibacterial agents are prescribed. ARD symptoms worsen the quality of life of patients. Complex treatment of respiratory diseases includes the prescription of symptomatic therapy: antipyretics, antitussives, vasoconstrictor drugs in rhinorrhea. Cough is the most common respiratory symptom. In various diseases, cough has its own peculiarities, which allows you to carry out differential diagnosis. The American Thoracic Society has proposed schemes of differential search for acute and chronic coughs, which allow rational diagnosis of diseases. The use of antitussive drugs has its own peculiarities: when the cough is non-productive, drugs are prescribed to suppress cough, when the cough is productive - drugs are aimed at facilitating the evacuation of sputum. One of the preparations possessing expectorant, mucolytic and antispasmodic action, is Hedelix syrup on the basis of ivy.

Acute respiratory diseases (ARD) are widespread diseases and are of great social importance. Diagnosis of acute respiratory infections implies the damage to the respiratory system caused by a wide range of pathogens. Among the pathogens of acute respiratory infections are viruses of acute respiratory viral infection (ARVI) group, including influenza, as well as fungal and bacterial pathogens, which include intracellular bacteria: mycoplasma and chlamydia. Diseases caused by intracellular pathogens are treated by antibacterial drugs that can easily penetrate the cells and create there high concentrations.

Summary: The article reveals current data on the epidemiology of acute respiratory infections and antiviral defense mechanisms with regard to the anatomical and physiological characteristics of children's immune system and options for etiopathogenetic therapy. The focus is on the antiviral and immunomodulatory drug pranobex inosine (Isoprinosine), with data from literature on the use of inosine pranobex in children with respiratory infections. The efficacy and safety of inosine pranobex (Isopinosine) in pediatric practice is demonstrated.

Respiratory infectious diseases represent one of the most common pathologies in outpatient care. Use of immunomodulators in multimodal treatment of infectious and inflammatory diseases has been widely discussed recently. Since immune modulation therapy is auxiliary and could not substitute etiotropic drugs, the limits for the use of immunomodulators in the treatment of infectious diseases should be clearly defined. Patients with immune deficiencies constitute a special risk group for infectious diseases. Both etiotropic and immunomodulatory therapy for such patients should be selected very carefully. The review summarizes data on immunomodulators used in Russia and discusses conditions for prescribing immunomodulatory therapy.